NYSEAMERICAN:APHB - Ampliphi Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.0910 -0.01 (-0.91 %)
(As of 07/16/2018 06:00 AM ET)
Previous Close$1.0910
Today's Range$1.0801 - $1.11
52-Week Range$0.70 - $2.05
Volume28,691 shs
Average Volume418,953 shs
Market Capitalization$21.87 million
P/E RatioN/A
Dividend YieldN/A
Beta2.76
Ampliphi Biosciences logoAmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections. AmpliPhi Biosciences Corporation has a collaboration agreement and a license agreement with the University of Leicester; and a collaboration agreement with the Western Sydney Local Health District and the Westmead Institute for Medical Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

Receive APHB News and Ratings via Email

Sign-up to receive the latest news and ratings for APHB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:APHB
CUSIPN/A
Phone+1-804-8272524

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2,050.00%
Return on Equity-31.85%
Return on Assets-21.63%

Miscellaneous

EmployeesN/A
Outstanding Shares16,460,000
Market Cap$21.87

The Truth About Cryptocurrencies

Ampliphi Biosciences (NYSEAMERICAN:APHB) Frequently Asked Questions

What is Ampliphi Biosciences' stock symbol?

Ampliphi Biosciences trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "APHB."

How were Ampliphi Biosciences' earnings last quarter?

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) posted its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.05. Ampliphi Biosciences had a negative return on equity of 31.85% and a negative net margin of 2,050.00%. View Ampliphi Biosciences' Earnings History.

When is Ampliphi Biosciences' next earnings date?

Ampliphi Biosciences is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Ampliphi Biosciences.

What price target have analysts set for APHB?

1 Wall Street analysts have issued 1 year price objectives for Ampliphi Biosciences' shares. Their predictions range from $6.00 to $6.00. On average, they expect Ampliphi Biosciences' stock price to reach $6.00 in the next year. This suggests a possible upside of 450.0% from the stock's current price. View Analyst Ratings for Ampliphi Biosciences.

What is the consensus analysts' recommendation for Ampliphi Biosciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ampliphi Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Ampliphi Biosciences?

Ampliphi Biosciences saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 868,512 shares, an increase of 0.5% from the May 31st total of 864,065 shares. Based on an average daily volume of 155,247 shares, the days-to-cover ratio is presently 5.6 days. Approximately 5.6% of the shares of the stock are sold short. View Ampliphi Biosciences' Current Options Chain.

Who are some of Ampliphi Biosciences' key competitors?

Who are Ampliphi Biosciences' key executives?

Ampliphi Biosciences' management team includes the folowing people:
  • Dr. Paul C. Grint, CEO & Director (Age 60)
  • Mr. Steven R. Martin, Sr. VP & CFO (Age 57)
  • Dr. Igor P. Bilinsky, Sr. VP & COO (Age 45)
  • Mr. Michael Scott Salka, Consultant (Age 56)
  • Dr. Alexander Gaidamaka, VP of Chemistry, Manufacturing & Control

Has Ampliphi Biosciences been receiving favorable news coverage?

Media headlines about APHB stock have been trending positive on Monday, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ampliphi Biosciences earned a media sentiment score of 0.29 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.66 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Ampliphi Biosciences?

Shares of APHB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ampliphi Biosciences' stock price today?

One share of APHB stock can currently be purchased for approximately $1.0910.

How big of a company is Ampliphi Biosciences?

Ampliphi Biosciences has a market capitalization of $21.87 million.

How can I contact Ampliphi Biosciences?

Ampliphi Biosciences' mailing address is 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States. The biotechnology company can be reached via phone at +1-804-8272524.


MarketBeat Community Rating for Ampliphi Biosciences (NYSEAMERICAN APHB)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Ampliphi Biosciences and other stocks. Vote "Outperform" if you believe APHB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APHB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.